These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 24132476)

  • 1. Capsid modification strategies for detargeting adenoviral vectors.
    Parker AL; Bradshaw AC; Alba R; Nicklin SA; Baker AH
    Methods Mol Biol; 2014; 1089():45-59. PubMed ID: 24132476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.
    Bradshaw AC; Coughlan L; Miller AM; Alba R; van Rooijen N; Nicklin SA; Baker AH
    J Control Release; 2012 Dec; 164(3):394-402. PubMed ID: 22626939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tropism-modification strategies for targeted gene delivery using adenoviral vectors.
    Coughlan L; Alba R; Parker AL; Bradshaw AC; McNeish IA; Nicklin SA; Baker AH
    Viruses; 2010 Oct; 2(10):2290-2355. PubMed ID: 21994621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells.
    Gaden F; Franqueville L; Magnusson MK; Hong SS; Merten MD; Lindholm L; Boulanger P
    J Virol; 2004 Jul; 78(13):7227-47. PubMed ID: 15194799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of adenoviral vectors by flow cytometry.
    Weaver LS; Kadan MJ
    Methods; 2000 Jul; 21(3):297-312. PubMed ID: 10873484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of chimeric adenoviral vectors to assess capsid neutralization determinants.
    Roy S; Clawson DS; Calcedo R; Lebherz C; Sanmiguel J; Wu D; Wilson JM
    Virology; 2005 Mar; 333(2):207-14. PubMed ID: 15721355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vector systems for prenatal gene therapy: principles of adenovirus design and production.
    Alba R; Baker AH; Nicklin SA
    Methods Mol Biol; 2012; 891():55-84. PubMed ID: 22648768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.
    Madisch I; Hofmayer S; Moritz C; Grintzalis A; Hainmueller J; Pring-Akerblom P; Heim A
    J Virol; 2007 Aug; 81(15):8270-81. PubMed ID: 17522221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.
    Campos SK; Barry MA
    Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor.
    Seregin SS; Hartman ZC; Appledorn DM; Godbehere S; Jiang H; Frank MM; Amalfitano A
    J Innate Immun; 2010; 2(4):353-9. PubMed ID: 20375551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fiber-modified adenoviruses for targeted gene therapy.
    Wu H; Curiel DT
    Methods Mol Biol; 2008; 434():113-32. PubMed ID: 18470642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers.
    Lecollinet S; Gavard F; Havenga MJ; Spiller OB; Lemckert A; Goudsmit J; Eloit M; Richardson J
    J Virol; 2006 Mar; 80(6):2747-59. PubMed ID: 16501084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quasi-atomic model of human adenovirus type 5 capsid.
    Fabry CM; Rosa-Calatrava M; Conway JF; Zubieta C; Cusack S; Ruigrok RW; Schoehn G
    EMBO J; 2005 May; 24(9):1645-54. PubMed ID: 15861131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors.
    Imler JL; Chartier C; Dreyer D; Dieterle A; Sainte-Marie M; Faure T; Pavirani A; Mehtali M
    Gene Ther; 1996 Jan; 3(1):75-84. PubMed ID: 8929914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of a short peptide ligand to the adenovirus fiber protein.
    Michael SI; Hong JS; Curiel DT; Engler JA
    Gene Ther; 1995 Nov; 2(9):660-8. PubMed ID: 8548556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX.
    Tang Y; Le LP; Matthews QL; Han T; Wu H; Curiel DT
    Virology; 2008 Aug; 377(2):391-400. PubMed ID: 18570971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts.
    Gahéry-Ségard H; Juillard V; Gaston J; Lengagne R; Pavirani A; Boulanger P; Guillet JG
    Eur J Immunol; 1997 Mar; 27(3):653-9. PubMed ID: 9079805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical targeting of adenovirus vectors for gene therapy.
    Silman NJ; Fooks AR
    Curr Opin Mol Ther; 2000 Oct; 2(5):524-31. PubMed ID: 11249755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid generation of adenovirus vector with a genetic modification in hexon protein.
    Di B; Mao Q; Zhao J; Li X; Wang D; Xia H
    J Biotechnol; 2012 Feb; 157(3):373-8. PubMed ID: 22226912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction.
    de Vrij J; Dautzenberg IJ; van den Hengel SK; Magnusson MK; Uil TG; Cramer SJ; Vellinga J; Verissimo CS; Lindholm L; Koppers-Lalic D; Hoeben RC
    Gene Ther; 2012 Sep; 19(9):899-906. PubMed ID: 22011643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.